Award
Alberta Purchasing #NOA 2024-0164
Formulate saRNA into Lipid Nanoparticle (LNP) formulation with iL2V02 composition, Synthesize and characterize 3 of each saRNA and mRNA
Recipient
Cytiva (formerly Precision Nanosystems)
Award Amount
$322,350.00
Ceiling
$322,350.00
Awarded
September 06, 2024
Identifier
NOA 2024-0164
The University of Alberta awarded a contract to Cytiva (formerly Precision Nanosystems) for specialized expertise and saRNA related technology to develop lipid nanoparticle (LNP) formulations, focusing on delivery, immunogenicity, and minimal reactogenicity for vaccine research against viral infectious diseases. The contract involves the formulation and characterization of saRNA and mRNA, with an obligated amount of $322,350.43. The award supports departmental research and vaccine development efforts.
Description
The University of Alberta awarded a contract for specialized expertise and saRNA related technology to carry out delivery, immunogenicity and minimal reactogenicity. Cytiva's technology is essential for the development of saRNA and mRNA and manufacturing of LNP formulations, critical for departmental research and advancements in vaccines against viral infectious diseases.